The Advanced Liver Disease Center offers comprehensive management of all liver diseases across the entire spectrum. The Center is a leader in the Southwestern United States in treatment of Hepatitis C, developing robust treatment experience with “difficult to treat” populations: end-stage renal disease, HIV co-infection and decompensated cirrhosis. Non-invasive staging of various liver diseases — including non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) — is performed with cutting-edge technology, such as vibration controlled transient and magnetic resonance elastography. The team is one of the region’s highest volume and most experienced centers for management of hepatocellular cancer, garnering designation as a Therasphere® Center of Excellence.
The Advanced Liver Disease Center offers patients access to cutting-edge therapies for NAFLD/NASH with a robust clinical trial program. In addition, the section performs several investigator-led studies evaluating outcomes with direct acting antiviral therapy for hepatitis C and liver transplantation. The portfolio of clinical and translational research continues to grow with the active and enrolling University of Arizona cirrhosis biobank.
- A five-year Longitudinal Observational Study of Patients with Primary Biliary Cholangitis.
- Emricasan, a Caspase Inhibitor, for Treatment of Subjects with Decompensated NASH Cirrhosis.
- A five-year Longitudinal Observational Study of Patients with Nonalcoholic Fatty Liver (NAFL) or Nonalcoholic Steatohepatitis (NASH).
- Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients with Nonalcoholic Steatohepatitis (NASH).